{"entity":{"id":"bios-life","kind":"company","name":"Bios Life","aka":[],"tldr":"Bios Life runs a virtual clinic for people who have finished cancer treatment or who carry a high inherited risk: a care team watches their risk over time and uses AI models to decide which scan or test should come next and when.","summary":"Bios Life describes itself as an AI-native cancer surveillance company. It combines multi-modality foundation models with direct patient care, delivered virtually by licensed care teams across the United States, to personalise screening for people at high risk and follow-up for cancer survivors. It emerged from stealth in August 2026 with USD 25 million in seed financing led by Redmile, Vsquared Ventures and Kindred Capital, and announced a multi-year alliance with Tempus giving it access to de-identified multimodal oncology datasets to train and validate its models, together with genetic screening through Ambry Genetics, a Tempus company. Its co-founders are chief executive Ryan Richardson and Zach Taylor, both formerly of BioNTech, and chief medical officer Logan Frank, a radiologist. The company said its platform would launch in the US in the second half of 2026.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.bioslife.ai/"},{"label":"Launch release and Tempus alliance, August 2026","url":"https://www.einpresswire.com/article/933138397/bios-life-emerges-from-stealth-with-25m-and-partners-with-tempus-to-personalize-cancer-screening-and-surveillance"}],"tags":[],"related":[],"cancers":[],"sections":["early-detection","ai-computation"],"technologies":["telehealth-oncology","survivorship-care-plan"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not stated. HQ is the Boston dateline of the launch release; the company website gives no address. Bios Life is a surveillance and care service, not a blood test for many cancers, so it is not counted as multi-cancer early detection. No outcome data had been published at the time of writing."],"hq":"Boston, MA","country":"US","companyType":"ai-software","website":"https://www.bioslife.ai/","stage":"startup","investors":[],"funding":[{"round":"Seed","year":2026,"amountUsd":25000000,"source":"https://www.einpresswire.com/article/933138397/bios-life-emerges-from-stealth-with-25m-and-partners-with-tempus-to-personalize-cancer-screening-and-surveillance","note":"Led by Redmile, Vsquared Ventures and Kindred Capital"}]},"route":"/companies/bios-life/","neighbours":{"section":[{"id":"ai-computation","kind":"section","name":"AI & Computation","route":"/fronts/ai-computation/"},{"id":"early-detection","kind":"section","name":"Early Detection & Screening","route":"/fronts/early-detection/"}],"technology":[{"id":"survivorship-care-plan","kind":"technology","name":"Survivorship care and late-effects surveillance","route":"/technologies/survivorship-care-plan/"},{"id":"telehealth-oncology","kind":"technology","name":"Telehealth and hospital-at-home in oncology","route":"/technologies/telehealth-oncology/"}]}}